On February 4, 2026, CEO John Marotta told investors Azenta was "entering the year well positioned for continued success" and reaffirmed FY 2026 guidance of 3%-5% organic revenue growth with approximately 300 basis points of adjusted EBITDA margin expansion. On May 5, 2026, the Company reported Q2 FY 2026 results that included a $149 million goodwill impairment charge in its Multiomics segment. The resulting net loss of $160.8 million stood in stark contrast to the growth trajectory management had presented ninety days prior.
Alongside the impairment, Azenta reduced its full-year FY 2026 guidance — trimming the revenue growth and margin expansion targets it had publicly reaffirmed in February. The gap between the Company's stated outlook and its reported results is now the subject of an investigation into potential securities law violations.
To receive more information, please fill out the form.
